Anticancer Activity of Bee Venom Components against Breast Cancer

Abstract

While the survival rate has increased due to treatments for breast cancer, the quality of life has decreased because of the side effects of chemotherapy. Various toxins are being developed as alternative breast cancer treatments, and bee venom is drawing attention as one of them. We analyzed the effect of bee venom and its components on breast cancer cells and reviewed the mechanism underlying the anticancer effects of bee venom. Data up to March 2022 were searched from PubMed, EMBASE, OASIS, KISS, and Science Direct online databases, and studies that met the inclusion criteria were reviewed. Among 612 studies, 11 were selected for this research. Diverse drugs were administered, including crude bee venom, melittin, phospholipase A2, and their complexes. All drugs reduced the number of breast cancer cells in proportion to the dose and time. The mechanisms of anticancer effects included cytotoxicity, apoptosis, cell targeting, gene expression regulation, and cell lysis. Summarily, bee venom and its components exert anticancer effects on human breast cancer cells. Depending on the mechanisms of anticancer effects, side effects are expected to be reduced by using various vehicles. Bee venom and its components have the potential to prevent and treat breast cancer in the future.

Investigation of Immunological Response of Egyptian Bee Venom Preparation in Rabbits

“…El-Fiky et al (2022) found that the bioactive components of bee venom can be used as an alternative to improve humans' health. Kwon et al (2022) reported that BV has anti-breast cancer activity. El Naggar et al (2023) reported that BV is a promising Apitherapy for chronic toxoplasmosis markedly enhanced by loaded metal organic frameworks.…”

Shaping the Future of Antimicrobial Therapy: Harnessing the Power of Antimicrobial Peptides in Biomedical Applications

“…Biomedical Application Peptide Surgical site infection (SSI) LL-37 [15], hBD2&3 [16], Protegrins [17], Histatins [18], Ranalexin [19], Pexiganan [20], Magainin [21], HNP1 [22] Contact lens-associated microbial keratitis (CLMK) α-MSH [23], Melimine [24], Pexiganan [25], Bacitracin [26], Dermcidin [27] Dental applications LL-37 [28], Dermaceptin [29], Nisin, Histatins [30], hBD1 [31], human beta-defensin-3 [32], human beta-defensin-5, Cateslytin [33], Myxinidin [34], HHC-36 [34] Bone-graft applications KLD [35], E14LKK [36] Tissue generation DermaceptinS4 [37], Thanatin [38], LLKKK18 [39], DPK-060 [40], SMAP-29 [41], G3KL [42], G3R, MSI-78 Anticancer agents pAntp [43], KT2 [44], RT2 [45], LL37 [46], LTX-315, [46] melittin [47]…”

Hybrid bio-nanoporous peptide loaded-polymer platforms with anticancer and antibacterial activities

“…, ovarian, prostate, breast, lung by affecting cell cycle, proliferation/growth, motility, migration, through a complex mechanism implying different signal transduction and regulatory pathways. 27–30…”